Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients

Marinko Marusic, Zarko Babic, Mirjana Nesanovic, Mira Lucijanic-Mlinac, Vesna Stajcar

Abstract

AIM: Intestinal metaplasia (IM) is more often found in patients with Helicobacter pylori (H pylori) infection, while eradication of H pylori results in significant reduction in the severity and activity of chronic gastritis. We aimed to determine in patients with unsuccessful eradication of H pylori the role of various proton pump inhibitors (PPIs) having different mechanisms in the resolution of IM.

METHODS: We confirmed endoscopically and pathohistologically (Sydney classification) the IM in 335 patients with gastritis before and after medication for eradication of H pylori (Maastricht Protocol 2002). H pylori infection was determined by using histology, urease test and culture. Control endoscopy and histology were done after 30 d and thereafter (within 1 year). Unsuccessful eradication was considered if only one of the three tests (histology, urease and culture) was negative after therapy protocol. We used omeprazole, pantoprazole, lansoprazole in therapy protocols (in combination with two antibiotics).

RESULTS: We found no significant difference in resolution of IM by using different PPI between the groups of eradicated and noneradicated patients (P<0.4821 and P<0.4388, respectively).

CONCLUSION: There is no significant difference in resolution of intestinal metaplasia by different proton pump inhibitors.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: H pylori, Intestinal metaplasia

Marusic M, Babic Z, Nesanovic M, Lucijanic-Mlinac M, Stajcar V. Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients. World J Gastroenterol 2005; 11(15): 2334-2336

http://www.wjgnet.com/1007-9327/11/2334.asp

INTRODUCTION

Patients with Helicobacter pylori (H pylori) infection have been found more frequently with intestinal metaplasia (IM) and atrophic gastritis. Several authors (Asaka et al, and Kokkola et al) have found that eradication of H pylori results in significant reduction in the severity and activity of chronic gastritis.

We know about different mechanisms of proton pump inhibitors (PPIs). Omeprazole and lansoprazole have effects on Cys 813, and pantoprazole additionally on Cys 822 which is important for irreversible acid blockade. The influence on gastric acid secretion is dose dependent, which means that a higher PPI dose has a stronger acid inhibition. H pylori eradication was associated with a histologic improvement of gastric mucosa but in uninfected patients no significant change in inflammation or proliferation occurred during treatment with lansoprazole.

The aim of this study was to determine in patients with unsuccessful eradication of H pylori the role of various PPIs having different mechanisms in the resolution of IM.

MATERIALS AND METHODS

Patients

We followed up 335 patients with gastritis (142 males and 193 females, mean age 51.3 years, between 18 and 83 years). All patients underwent upper gastrointestinal endoscopy with pathohistologic examination. We used Olympus Q20 and Pentax video endoscopy systems.

Methods

Diagnostic procedures. We confirmed endoscopically and pathohistologically (Sydney classification) the IM in patients with gastritis before and after medication for eradication of H pylori (Maastricht Protocol 2002). H pylori infection was determined by using histology, urease test and culture in addition to E-test. Control endoscopy and histology were done after 30 d and thereafter (within 1 year). Unsuccessful eradication was considered if only one of the three tests (histology, urease and culture) was positive after therapy protocol.

Therapy. We used omeprazole 20 mg bid, pantoprazole 40 mg bid, and lansoprazole 30 mg bid in eradication therapy.
protocols during 7 d in combination with two antibiotics (amoxicillin 1 g bid and clarithromycin 500 mg bid), and thereafter at the same dose but once a day during the next 4 wk. We included 108 patients on omeprazole protocol, 137 patients on pantoprazole protocol and 90 patients on lansoprazole protocol.

RESULTS
The successful eradication of H pylori led to the disappearance of IM in gastric mucosa (208 patients with negative IM vs 19 patients with positive IM) \( (x^2 = 157.36, \gamma = 1, P<0.001) \). The unsuccessful eradication of H pylori also led to the disappearance of IM but it was not statistically significant (48 with positive IM vs 60 with negative IM; \( x^2 = 1.33, \gamma = 1, P<0.1 \)).

We found no significant difference in resolution of IM by using different PPI in the group of noneradicated patients \( (P<0.4821) \), as well as in the group of eradicated patients \( (P<0.4388) \) (Tables 1 and 2).

DISCUSSION
The occurrence of IM was influenced by the presence of H pylori infection\(^{[1,2]}\). H pylori modified cellular processes of the host and led to inflammation\(^{[1,2]}\). H pylori infection stimulated the infiltration of neutrophils, lymphocytes, plasma cells and macrophages in gastric mucosa\(^{[10]}\). There are several mechanisms by which H pylori infection triggers a host response (major histocompatibility complex II, translocation of \( H pylori \) CagA protein into human gastric epithelial cells using type IV secretion which is ATP-ase dependent)\(^{[10]}\). PPI could influence ATP-ase and glycoprotein\(^{[11]}\). \( H pylori \) could also influence lamina propria and activate underlying cells\(^{[10]}\). They could influence host response to their presence by regulating prostaglandin production over cyclo-oxygenase-2-expression, activating neutrophils and oxidative stress and mucosal products, and all these processes could result in apoptosis and cell proliferation suppression\(^{[10]}\). Specific gene products synthesized by bacteria or host have been implicated in the inflammatory and IM process (role of cag potency in IM and gastric cancer development)\(^{[10]}\).

The gastritis score increased in patients who had no or only mild corpus gastritis before treatment and significantly decreased in those who had moderate or severe gastritis before treatment\(^{[13]}\). We could find similar results in the study of Berstad et al\(^{[3]}\), with lansoprazole.

Acid secretion decreased dose-dependently in PPI users\(^{[13,14]}\). Reports on endocrine cell changes in the antral mucosa under chronic PPI therapy are controversial and lack clinical relevance\(^{[14,15]}\). Data on the progression of oxintic gastritis under chronic PPI treatment in comparison to untreated controls could not be confirmed in more recent studies including a well-matched control population\(^{[16]}\). The mechanism of PPI action on acid suppression is different. All PPIs bind to and act on Cys 813, which is placed near the curve where TM6 enters the membrane domain. Lansoprazole binds to Cys 321 on ectoplasmatic end TM3, but pantoprazole binds to Cys 822 which is placed deeper in the membrane domain TM6\(^{[16]}\). This can be an explanation for different and irreversible suppressions of Cys 822 by pantoprazole. The recovery of proton pump was measured in rat stomach, and complete recovery of ATP-ase was detected after medication with omeprazole, esomeprazole and rabeprazole but 70% recovery was detected. After medication with pantoprazole no recovery of proton pump was detected after lansoprazole\(^{[16]}\). We wanted to evaluate the influence of PPI on IM in patients with similar conditions (inflammation caused by \( H pylori \)). Eradication of \( H pylori \) had no difference on IM disappearance by PPI. We concluded that there was no difference in PPIs between such groups of patients. In the group of patients with unsuccessful eradication of \( H pylori \), presence of \( H pylori \) was constant, and PPI could influence IM, but our results were negative. The explanation can be that \( H pylori \) disturbs the effect of PPI on IM disappearance in a different way from the mechanism by which it acts on PPI in gastric cells. But it is interesting that in the eradicated group (effect of \( H pylori \) on gastric cells excluded) the result was the same. Further investigations are needed.

REFERENCES
1. Ohkuma K, Okada M, Murayama H, Seo M, Maeda K, Kanda M, Okabe N. Association of Helicobacter pylori infection with atrophic gastritis and intestinal metaplasia. J Gastroenterol Hepatol 2000; 15: 1105-1112
2. Kokkola A, Sipponen P, Rautelin H, Harkonen M, Kosunen TU, Haapiainen R, Puolakkainen P. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther 2002; 16: 515-520
3. Welage LS. Pharmacocinetic comparison of five proton pump inhibitors. Gastroenterology 2002; 122(Suppl-): S130-S133
4. Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzæg P, Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997; 41: 740-747
5. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161-1181
6. Malferttheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the

Table 1 Influence of various PPIs on intestinal metaplasia in the noneradicated Helicobacter pylori infection patients

| Intestinal metaplasia | Omeprazole (n) | Pantoprazole (n) | Lansoprazole (n) |
|----------------------|----------------|-----------------|-----------------|
| Negative             | 20             | 26              | 14              |
| Positive             | 16             | 22              | 10              |

\( \chi^2 = 2.462, \gamma = 3, P = 0.4821 \)

Table 2 Influence of various PPIs on intestinal metaplasia in the eradicated Helicobacter pylori infection patients

| Intestinal metaplasia | Omeprazole (n) | Pantoprazole (n) | Lansoprazole (n) |
|----------------------|----------------|-----------------|-----------------|
| Negative             | 64             | 81              | 63              |
| Positive             | 8              | 8               | 3               |

\( \chi^2 = 2.702, \gamma = 3, P = 0.4388 \)
management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report. *Aliment Pharmacol Ther* 2002; 16: 167-180

7 Megraud F, Henzel S, Glupczynski Y. Antibiotic susceptibility and resistance in *Helicobacter pylori*: physiology and genetics. *ASM Press* 2001: 511-530

8 Chaves S, Gadanho M, Tenreiro R, Cabrita J. Assessment of metronidazole susceptibility in *Helicobacter pylori*: statistical validation and error rate analysis of breakpoints determined by the disk diffusion test. *J Clin Microbiol* 1999; 37: 1628-1631

9 Cederbrant G, Kahlmeter G, Ljungh A. The E test for antimicrobial susceptibility testing of *Helicobacter pylori*. *J Antimicrob Chemother* 1993; 31: 65-71

10 Eliot SN, Ernst PB, Kelly CP. Molecular inflammation. *Current Opinion Gastroenterol* 2001; 17 (Suppl 1): S12-16

11 Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. *Naunyn Schmiedebergs Arch Pharmacol* 2001; 364: 551-557

12 Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Mashiba H, Sasaki N, Taniyama K. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid suppressive treatment in Japan. *Aliment Pharmacol Ther* 2000; 14: 1345-1352

13 Muller P, Goksu MA, Fuchs W, Schluter F, Simon B. Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion—a placebo-controlled study in healthy volunteers. *Aliment Pharmacol Ther* 2000; 14: 1225-1229

14 Stolte M, Meining A. Changes in Helicobacter pylori gastritis caused by therapy with inhibitors of gastric acid secretion. *Z Gastroenterol* 1999; 37: 1029-1036

15 Lamberts R. Morphological changes of the human gastric mucosa under long-term proton pump inhibitor therapy and their clinical relevance. *Microsc Res Tech* 2000; 48: 357-366

16 Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. *Gastroenterology* 2002; 123: 1588-1597